These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1471164)

  • 1. Molecular basis for differences in susceptibility to toxicants: introduction.
    Boobis AR
    Toxicol Lett; 1992 Dec; 64-65 Spec No():109-13. PubMed ID: 1471164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
    Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotyping of drug metabolism in infants and children: potentials and problems.
    Rane A
    Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
    [No Abstract]   [Full Text] [Related]  

  • 6. Populations and genetic polymorphisms.
    Weber WW
    Mol Diagn; 1999 Dec; 4(4):299-307. PubMed ID: 10671640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of genetic polymorphisms of drug metabolism.
    Meyer UA; Zanger UM
    Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.
    Brockmöller J; Cascorbi I; Kerb R; Roots I
    Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.
    Agúndez JA; Martínez C; Olivera M; Gallardo L; Ladero JM; Rosado C; Prados J; Rodriguez-Molina J; Resel L; Benítez J
    Br J Cancer; 1998 Nov; 78(10):1361-7. PubMed ID: 9823980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
    Daly AK; Cholerton S; Armstrong M; Idle JR
    Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):55-61. PubMed ID: 7698086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk.
    Spurr NK; Gough AC; Chinegwundoh FI; Smith CA
    Clin Chem; 1995 Dec; 41(12 Pt 2):1864-9. PubMed ID: 7497646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Individualization of drug therapy and pharmacogenetics].
    Yamamoto I; Azuma J
    Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of genetic polymorphisms in risk assessment of drugs.
    Poulsen HE; Loft S
    Arch Toxicol Suppl; 1994; 16():211-22. PubMed ID: 8192584
    [No Abstract]   [Full Text] [Related]  

  • 15. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
    Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
    Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics.
    Wolf CR; Smith G
    Br Med Bull; 1999; 55(2):366-86. PubMed ID: 10723863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
    Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically determined adverse drug reactions involving metabolism.
    Lennard MS
    Drug Saf; 1993 Jul; 9(1):60-77. PubMed ID: 8347292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.